Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

On the Couch

On the Couch artwork

On the Couch with Dr. Deborah Rathjen and Dr. Michael Baker: Fighting Cancer with CAR-T

Dec 3, 202434 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In the special episode of 'On the Couch', Henry Jennings sits down with two medical pioneers in the CAR-T field, who are leading the charge in the search for cures for various cancers. Dr. Deborah Rathjen, CEO and MD of Carina Biotech, represents a small, unlisted Adelaide-based company funded by the Forest Foundation. Carina Biotech focuses on treatments for solid cancers. Dr. Michael Baker, CEO and MD of Arovella (ASX: ALA), leads a listed Melbourne-based company progressing to Phase One human trials for a new drug to treat blood cancers. CAR-T therapy is a type of personalised cancer immunotherapy treatment. CAR-T stands for 'Chimeric Antigen Receptor T-cell', named after the chimera - a fire-breathing monster in Greek mythology made up of different animal parts. This therapy utilises a specific type of immune cell called a 'T cell'. T cells are one type of immune cell found in our bloodstream. Think of them as soldiers, constantly on patrol, surveying for threats such as microbes, bacteria, viruses, and, in some cases, cancer cells. For CAR-T, T cells are genetically altered in the laboratory, often with the help of a friendly virus. These cells are then "armed" with a specific receptor on their surface, enabling them to recognise, bind to, and destroy specific cancer cells. Once the CAR-T cells are armed, they are grown into hundreds of millions - or even billions - and reinfused into the patient. This process empowers the patient's own immune system to hunt down and fight their cancer. Each type of CAR-T cell therapy is designed to recognise and target a specific marker or "antigen" on a cancer cell. Disclaimer: This is general advice only and you should consult your financial adviser regarding any of the thoughts, ideas or insights in this podcast. Why not sign up for a free trial? Get access to expert insights and research and become a better investor.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. On the Couch with Dr Samantha South (ASX: PAB): Repurposing an Established Drug for Delirium

    Nov 20, 202629 minAudio

    In this episode of On the Couch, Henry Jennings speaks with Dr Samantha South, CEO of Patrys (ASX: PAB). Samantha explains delirium, an acute brain dysfunction that can cause confusion, agitation and hallucinations, and...

    Credit the people on this episode

  2. On the Couch with Ryan MacNeill (ASX: EQR): Why Tungsten Is in Focus at IMARC 2026

    Nov 20, 202616 minAudio

    In this episode of On the Couch, Henry Jennings sits down with Ryan MacNeill, General Manager of Sales and Marketing at EQ Resources (ASX: EQR), at the International Mining and Resources Conference (IMARC) 2026....

    Credit the people on this episode

  3. On the Couch with Richard Morrow (ASX: LRT): Copper, Gold and Critical Minerals at IMARC 2026

    Nov 13, 202615 minAudio

    In this episode of On the Couch, Henry Jennings sits down with Richard Morrow, Director of Lowell Resources Funds Management, at the International Mining and Resources Conference (IMARC) 2026. Recorded live in the OnAir...

    Credit the people on this episode

  4. On the Couch with Jim McKerlie (ASX: IPT): From Explorer to Advanced Materials at IMARC 2026

    Nov 13, 202616 minAudio

    In this episode of On the Couch, Henry Jennings sits down with Jim McKerlie, Chairman of Impact Minerals (ASX: IPT), at the International Mining and Resources Conference (IMARC) 2026. Recorded live in the OnAir podcast...

    Credit the people on this episode

  5. On the Couch with David Newling (ASX: AR1): Why Queensland Copper Is Consolidating at IMARC 2026

    Nov 11, 202611 minAudio

    In this episode of On the Couch, Henry Jennings speaks with David Newling, Chairman of Austral Resources (ASX: AR1), at the International Mining and Resources Conference (IMARC) 2026. Recorded live in the OnAir podcast...

    Credit the people on this episode